Aidwell Lifesciences Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 15-06-2024
- Paid Up Capital ₹ 0.10 M
as on 15-06-2024
- Company Age 9 Year, 4 Months
- Last Filing with ROC 31 Mar 2023
- Revenue -12.97%
(FY 2023)
- Profit 257.77%
(FY 2023)
- Ebitda -6937.72%
(FY 2023)
- Net Worth 33.72%
(FY 2023)
- Total Assets -16.49%
(FY 2023)
About Aidwell Lifesciences
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Meghraj Chaudhary, Nareshbhai Patel, Asmeetaben Bavarava, and Two other members serve as directors at the Company.
- CIN/LLPIN
U24100GJ2015PTC084153
- Company No.
084153
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
10 Aug 2015
- Date of AGM
19 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Ahmedabad
Industry
Company Details
- Location
Ahmedabad, Gujarat, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Aidwell Lifesciences?
Board Members(5)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Meghraj Chaudhary  | Director | 10-Aug-2015 | Current |
| Nareshbhai Patel | Director | 10-Aug-2015 | Current |
| Asmeetaben Bavarava | Director | 05-Dec-2019 | Current |
| Arvindbhai Chaudhari | Director | 05-Dec-2019 | Current |
| Ravikumar Joshi | Director | 05-Dec-2019 | Current |
Financial Performance of Aidwell Lifesciences.
Aidwell Lifesciences Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 12.97% decrease. The company also saw a substantial improvement in profitability, with a 257.77% increase in profit. The company's net worth Soared by an impressive increase of 33.72%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Aidwell Lifesciences?
In 2023, Aidwell Lifesciences had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Aidwell Univet Private LimitedActive 5 years 9 monthsMeghraj Chaudhary and Asmeetaben Bavarava are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Aidwell Lifesciences?
Aidwell Lifesciences has a workforce of 6 employees as of Mar 26, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Aidwell Lifesciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Aidwell Lifesciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
